Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
- Author:
Jun-Hong DENG
1
;
Liu-Ping YANG
;
Liang-Sheng WANG
;
De-Fan ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgens; deficiency; Bone Density; Bone Diseases, Metabolic; diagnosis; etiology; Gonadotropin-Releasing Hormone; therapeutic use; Humans; Male; Orchiectomy; adverse effects; Osteoporosis; diagnosis; etiology; Prostatic Neoplasms; therapy
- From: Asian Journal of Andrology 2004;6(1):75-77
- CountryChina
- Language:English
-
Abstract:
AIMTo evaluate the effect of androgen deprivation therapy (ADT) on bone mineral density (BMD) in prostate cancer patients.
METHODSForty-nine prostate cancer patients with their BMD determined were divided into two groups: the non-treated group included 21 patients before the commencement of ADT and the treated group, 28 patients, who had received ADT for more than 1 year. BMD was measured by dual energy X-ray absorptiometry (DEXA) in the lumbar spine (L2-4) and femoral neck.
RESULTSThirteen (62 %) non-treated and 23 (82 %) treated patients fulfilled the BMD criteria for osteopenia or osteoporosis. Z scores for age-matched control in lumbar spine and femoral neck were -0.9 +/- 0.7 and -0.6 +/- 0.5, respectively, in the treated group, and -1.8 +/- 1.1 and -1.6 +/- 1.0, respectively, in the non-treated group, the differences between the two groups were highly significant (P<0.01).
CONCLUSIONProstate cancer patients who received ADT for more than 1 year had a significantly lower BMD in the lumbar spine and femoral neck than those before the beginning of ADT.
